ダブル室容積脈波による意識下マウスにおける呼吸機能の評価

Executive Industry Relevance

Assessing respiratory function in conscious animals is critical for preclinical safety pharmacology and respiratory drug development, where maintaining physiological relevance improves translational confidence. Double-chamber plethysmography enables non-invasive, repeated measurements of breathing patterns and airway resistance in unrestrained, spontaneously breathing mice, supporting mechanistic de-risking of inhaled therapeutics. The technique provides quantitative, reproducible readouts that align with early discovery to lead optimization workflows by delivering reliable baseline and challenge-response data without anesthetic confounders.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses related to airway reactivity and bronchoconstriction pathways in disease models.
• Operational Value: Supports functional target validation by measuring physiological outputs in conscious animals under baseline and challenged conditions.
• Predictive Value: Provides respiratory function readouts that help de-risk target engagement and mechanism of action in early-stage programs.

Screening & Assay Development

• Assay Readiness: Delivers standardized, quantitative parameters such as specific airway resistance, tidal volume, and minute ventilation for compound screening.
• Reproducibility: Enables parallel monitoring of multiple animals and repeated assessments over days, improving assay robustness.
• Scalability: Compatible with aerosolized substance administration, supporting dose-response profiling in safety pharmacology.

Translational & Preclinical Research

• Disease Relevance: Demonstrated utility in allergic inflammation models, enabling evaluation of genotype-phenotype correlations in respiratory disease.
• Translational Continuity: Connects discovery-phase respiratory phenotypes to preclinical validation through consistent, anesthesia-free measurements.
• Risk-Adjusted Decisions: Facilitates go/no-go assessments by quantifying responsiveness to bronchoconstrictive agents like methacholine across experimental groups.

Pipeline & Workflow Integration

The method fits within the discovery continuum from target validation through lead identification to preclinical evaluation, particularly for respiratory and inhaled therapeutic programs requiring functional respiratory endpoints.

• Discovery Biology: Supports hypothesis testing of airway obstruction mechanisms and pathway modulation in genetic or disease models.
• Screening: Enables assay standardization and reproducible quantification of respiratory parameters for compound effect assessment.
• Analytics: Provides breathe-by-breathe calculated parameters including specific airway resistance and flow metrics for comparative condition analysis.
• Translational Research: Maintains physiological continuity from in vivo discovery to preclinical studies by avoiding anesthetic artifacts.
• Enterprise Reuse: Functions as a reusable platform for longitudinal respiratory monitoring across multiple studies and compound series.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence by delivering physiologically relevant respiratory data in conscious, unrestrained animals.
• Operational Value: Ensures standardization, reproducibility, and minimal procedural bias through acclimatization and bias flow control.
• Strategic Value: Improves go/no-go decision-making by reducing false positives from anesthetic or stress-induced respiratory artifacts.
• Portfolio Impact: Enables risk-adjusted prioritization of respiratory compounds based on validated, repeatable airway resistance measurements.

Implementation Considerations

• Requires expertise in animal handling, restrainer use, and plethysmograph system operation.
• Depends on calibrated instrumentation, bias flow generators, and nebulizer systems for aerosol delivery.
• Necessitates cross-team standardization of acclimatization protocols and environmental controls to minimize data variability.
• Involves adaptation considerations across mouse strains and disease models, as demonstrated in BALB/c and C57BL/6 backgrounds.
• Limited by potential hair leaks and chamber seal integrity, which can be mitigated through proper animal acclimatization and quiet experimental conditions.

Biopharma FAQs